基于pyridone的EZH2抑制剂抗癌候选药物:合成方法,比较分析和未来的前景
1Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt.
Future medicinal chemistry
|February 24, 2026
概括
基于皮里的小分子是有效的EZH2抑制剂,通过调节基因表达来向癌症至关重要. 本综述详细介绍了它们的合成,设计和优化,用于开发新的抗癌药物.
科学领域:
- 药用化学 医学化学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 在瘤学瘤学.
背景情况:
- 增强Zeste同源2 (EZH2) 是一个关键的表观遗传调节剂.
- EZH2失调通过H3K27三甲基化和瘤抑制基因沉默促进瘤发生.
研究的目的:
- 提供基于皮里的EZH2.2小分子抑制剂的全面审查.
- 讨论合成方法,脚手架设计和结构-活动关系.
- 突出抑制剂优化的进展和未来的方向.
主要方法:
- 文献综述侧重于EZH2抑制剂的合成策略和结构-活性关系.
- 对形状限制,尾部组优化和混合分子设计的分析.
- 对ADME和药物相似性质的比较分析.
主要成果:
- 基于pyridone的小分子是强大,选择性和对突变耐受的EZH2抑制的主要化类型.
- 进步包括构造限制,尾部组优化和针对多个途径的混合分子.
- 已经确定了强度和药理动学的关键分子决定因素.
结论:
- 基于皮里的EZH2抑制剂在癌症治疗中显示出显著的前景.
- 合理的设计和优化策略对于开发下一代抗癌候选药物至关重要.
- 对混合分子和药理动力学优化的进一步研究是有必要的.
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Drug Discovery: Overview
12.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.3K
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K


